Press Releases
We Are Contacting You as a Reminder of a Critical Shareholder Vote. InspireMD Inc. Urges Shareholders to Vote FOR Reverse Stock Split Proposal
VOTE NOW BY CALLING KINGSDALE ADVISORS AT 1-866-581-1479.or collect at 1-416-867-2272 AND ONE OF OUR AGENTS WOULD BE HAPPY TO TAKE YOUR VOTE OVER THE PHONE. Dear InspireMD Inc. (NSPR) Holdings Shareholder:  You should have already received proxy material related to InspireMD Inc.’s special shareholder meeting on March 17, 2021. AMONG THE PROPOSALS SHAREHOLDERS… Read More
InspireMD Announces Fourth Quarter and Year-End 2020 Financial Results
Management to host investor conference call today, March 9, at 8:30am ET Tel Aviv, Israel— March 9, 2021 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results for the fourth… Read More
InspireMD to Report Fourth Quarter and Year-End 2020 Financial Results on Tuesday, March 9, 2021 and Provide Corporate Update
Earnings conference call to be held Tuesday, March 9, 2021 at 8:30 a.m. ET Tel Aviv, Israel — March 2, 2021 – InspireMD, Inc. (NYSE American: NSPR) (“InspireMD” or the “Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it… Read More
InspireMD Engages Hart Clinical Consultants to Conduct Clinical Trial for CGuard Carotid Stent System in the United States
Tel Aviv, Israel – February 24, 2021 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart Clinical Consultants (HCC), a leading Contract Research Organization (CRO) to conduct the clinical trial for its CGuard… Read More
InspireMD Appoints Leading Interventional Cardiologist Chris Metzger, M.D. as Principal Investigator for CGuard Registration Trial in the United States
Tel Aviv, Israel – February 9, 2021 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, announced today the appointment of Chris Metzger, M.D., system chair of clinical research at Ballad Health System in Eastern Tennessee as the principal… Read More
INSPIREMD ANNOUNCES CLOSING OF AN UPSIZED $20.7 MILLION UNDERWRITTEN PUBLIC OFFERING AND FULL EXERCISE OF OVER-ALLOTMENT OPTION
Tel Aviv, Israel, Feb. 08, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (“InspireMD”) (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet™ stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East and Asia, today announced the closing of an upsized underwritten public… Read More
INSPIREMD ANNOUNCES PRICING OF UPSIZED $18 MILLION UNDERWRITTEN PUBLIC OFFERING
Tel Aviv, Israel / February 4, 2021 / InspireMD, Inc. (“InspireMD”) (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet™ stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East and Asia, today announced the pricing of an upsized underwritten public offering of… Read More
InspireMD Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China
New Chinese Distributor Will Also Invest in At-The-Market Private Placement Tel Aviv, Israel – February 3, 2021 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today announced a transaction intended to achieve distribution of CGuard EPS in… Read More
InspireMD’s CGuard™ Featured in Multiple Presentations, Including a Live Case Demonstration During the Leipzig Interventional Congress January 25-29, 2021
Tel Aviv, Israel – January 26, 2021 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, announced today multiple presentations regarding CGuard EPS, including a live demonstration, during the Leipzig Interventional Congress being held virtually from January 25-29, 2021…. Read More
InspireMD Announces Third Quarter 2020 Financial Results
Third quarter 2020 revenue returns to pre-COVID-19 levels Management to host investor conference call today, November 9, 2020 at 8:30 a.m. ET  Tel Aviv, Israel— November 9, 2020 – InspireMD, Inc. (NYSE American: NSPR)(“Inspire” or the “Company”), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment… Read More